Drug intelligence / Profile preview

MSC-NVs

Development stage: Preclinical
Modality: Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Intravenous, Intraperitoneal, Intranasal, Inhalation

Overview

MSC-NVs are mesenchymal stem cell (MSC)-derived nanovesicles. A specific variant, PMSC-NVs, is functionalized with the peptide GSPREYTSYMPH (PREY) to enable targeting of disturbed flow sites. These nanovesicles are produced from human MSCs (hMSCs) using plasmid DNA designed to functionalize the cell membrane with PREY. MSC-NVs demonstrate potent anti-inflammatory and pro-endothelial recovery effects, similar to those of hMSCs. They are being investigated as a nanoscale platform for theragnostic strategies aimed at preventing the progression of atherosclerosis by targeting early atherogenic events like disturbed flow formation and subsequent monocyte recruitment.

Beyond the preview

Go deeper on MSC-NVs.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MSC-NVs.

Explore the full profile